New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
05:55 EDTSPPI, SPPI, WAT, WAT, HSIC, HSIC, ISIS, ISIS, THOR, THOR, GWAY, GWAY, HRC, HRC, HWAY, HWAY, MYGN, MYGN, BMRN, BMRN, DRRX, DRRX, MCK, MCKCredit Suisse to host a conference
2012 Healthcare Conference is being held in Phoenix on November 14-15.
News For MCK;DRRX;BMRN;MYGN;HWAY;HRC;GWAY;THOR;ISIS;HSIC;WAT;SPPI From The Last 14 Days
Check below for free stories on MCK;DRRX;BMRN;MYGN;HWAY;HRC;GWAY;THOR;ISIS;HSIC;WAT;SPPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
10:28 EDTHWAYHealthways upgraded to Buy from Neutral at Dougherty (pre-open)
July 23, 2014
16:13 EDTHWAYHealthways sees profit margins improving in 2H14
Healthways expects that profit margins will improve in the second half of 2014 compared with the first half of the year, primarily due to continued revenue growth, including recognition of performance-based fees. Healthways also continues to expect operating cash flow for the full year of $75M-$85M, total capital expenditures of $40M-$45M and improvement in the ratio of total debt to EBITDA, as calculated under its credit agreement.
16:12 EDTHWAYHealthways reaffirms FY14 adjusted EPS view 11c-26c, consensus 20c
Reaffirms FY14 revenue view $730M-$760M, consensus $741.14M Reaffirms FY14 adjusted EBITDA margin 10.5%-11.5%.
16:11 EDTHWAYHealthways reports Q2 adjusted EPS 1c, consensus 0c
Reports Q2 revenue $180.6M, consensus $179.73M.
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Subscribe for More Information
July 22, 2014
13:05 EDTWATWaters shares should be bought, says Maxim
Subscribe for More Information
09:49 EDTWATWaters acquires REIMS technology from MediMass
Subscribe for More Information
08:53 EDTWATWaters narrows FY14 EPS view to $5.25-$5.40 from $5.25-$5.50
Consensus is $5.31. Organic sales growth at or above mid single digit range. Sees mid-to-high single digit top line growth in 2H. Sees government funded instrument sales in the U.S. increasing in 2H. Says governmental spending in China beginning to improve. Sees sales growth in Q3, Q4 that would result in FY14 constant currency mid single digit growth. Says still working to find a successor to CEO Douglas Berthiaume. Sees FY operating tax rate 14%-15%. Sees currency neutral to sales growth in FY. Sees FY gross margins 58.5%-59%.
08:52 EDTWATWaters sees Q3 EPS $1.22-$1.32, consensus $1.32
Subscribe for More Information
07:06 EDTWATWaters reports Q2 adjusted EPS $1.22, consensus $1.21
Subscribe for More Information
July 17, 2014
10:00 EDTWATOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
06:21 EDTWATWaters initiated with a Neutral at Citigroup
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
July 15, 2014
10:56 EDTBMRNFed calls small cap social media, biotech valuations 'stretched'
The Board of Governors of the Federal Reserve in its Monetary Policy Report dated today said valuation metrics in "some sectors" appear substantially stretched, "particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year." A later part in the document reads, "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The specific targeting of sectors by the Fed seems to be having an impact on stocks in the social media and biotech spaces. Shares of Yelp (YELP) are down over 5% to $67.51, while Twitter (TWTR) and Facebook (FB) are each down 2%. Celgene (CELG) and Amgen (AMGN) are leading the biotech space lower with pullbacks of greater than 1%.
July 14, 2014
07:20 EDTDRRXControlled Released Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use